Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332293 · ClinicalTrials.gov registry record · Phase 3
AL-15469A for the Treatment of Bacterial Conjunctivitis
A Phase 3 study of Bacterial Conjunctivitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 695
- Enrollment target
- 1
- Study location
NCT00332293 is a Phase 3 study of Bacterial Conjunctivitis that has completed, run by Alcon Research. The registered enrollment target is 695 participants, above the 526-participant average among 7 other Bacterial Conjunctivitis trials with a reported enrollment target (32% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00332293, a Phase 3 study of Bacterial Conjunctivitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 695 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.
Conditions Studied
Interventions
- DRUG Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%
- DRUG Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Study Locations (1)
Texas
- Contact Alcon for Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 695 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00332293
The ClinicalTrials.gov registry entry for NCT00332293 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 695 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 526-participant average among 7 other Bacterial Conjunctivitis trials with a reported enrollment target (32% higher). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bacterial Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5% is the first listed.
NCT00332293 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00332293 about?
NCT00332293 is a clinical study titled "AL-15469A for the Treatment of Bacterial Conjunctivitis". The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.
What is the current status of trial NCT00332293?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 695 participants. The study started on 2006-05. Estimated completion is 2006-12.
What conditions does trial NCT00332293 study?
This clinical trial studies the following conditions: Bacterial Conjunctivitis.
What interventions are being tested in trial NCT00332293?
The interventions under investigation include: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5% (DRUG), Moxifloxacin hydrochloride ophthalmic solution 0.5% as base (DRUG).
Who is sponsoring clinical trial NCT00332293?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00332293 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
RECRUITING · Phase 3
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
COMPLETED · Phase 3
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
COMPLETED · Phase 3
-
AL-15469A for the Treatment of Bacterial Conjunctivitis
COMPLETED · Phase 3
-
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
COMPLETED · Phase 3
-
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.